Artelo Biosciences Inc ARTL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.16
- Day Range
- $1.15–1.21
- 52-Week Range
- $0.99–49.53
- Bid/Ask
- $0.88 / $1.29
- Shares Outstanding
- 3.49M
- Market Cap
- $4.01M
- Volume/Avg
- 451 / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 7
- Website
- https://www.artelobio.com
Valuation
|
Metric
|
ARTL
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.15 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ARTL
|
|---|---|
Quick Ratio | 1.76 |
Current Ratio | 1.79 |
Interest Coverage | −32.56 |
Quick Ratio
ARTL
Profitability
|
Metric
|
ARTL
|
|---|---|
Return on Assets (Normalized) | −199.50% |
Return on Equity (Normalized) | −1,365.06% |
Return on Invested Capital (Normalized) | −718.89% |
Return on Assets
ARTL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|??FmvhH | LOCK|#?$^ | $121B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|$J>^S! | LOCK|#<Vhw | $70B | |||
| argenx SE ADR
ARGX
| LOCK|J!b@^cP | LOCK|#> | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Mkpb?#X | LOCK|@F?q | $37B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|C>NK!f? | LOCK|Lfn | $37B | |||
| Moderna Inc
MRNA
| LOCK|gq$f^Xx | LOCK|S! | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|?Vb<!@g | LOCK|sxy#@ | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|WB%>$lg | LOCK|<> | $23B | |||
| Incyte Corp
INCY
| LOCK|&KSh>Kh | LOCK|VV | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|W<&<bry | LOCK|D&R | $16B |
United States